UnitedHealth Group falls 2.91%, after major investor reduces stake and bearish signals mount

Traders Union
All News
Financial News
Unitedhealth group slides 2.91% today

All news

Editors' Picks

Crypto News

Financial News

Market Voices

Billionaires

Companies

Broker News

Regulators News

Ashutosh Sureka

18.11.2025

UnitedHealth Group falls 2.91%, after major investor reduces stake and bearish signals mount — Unitedhealth group slides 2.91% today

UnitedHealth Group Incorporated (UNH) is trading at $311.07, well below its MA-20 ($341.29), MA-50 ($347.65), and MA-200 ($375.11), signaling ongoing short-, medium-, and long-term selling pressure. The closest dynamic resistance is the Ichimoku Kijun line at $347.59, while there is no immediate support from major moving averages near the current price.

UNH price prediction

24H 4.59%

$415.06

48H 4.86%

$416.13

7D 4.18%

$413.46

1M 5.32%

$417.96

3M -18.05%

$325.22

6M 15.12%

$456.88

12M 27.1%

$504.42

Detailed

Current price: $ 396.86 20.31 5.39%

Real-time Data 15:10

Daily range 394.32

401.20

Weekly range 374.72

386.35

Highlights

Frank Rimerman Advisors LLC cut its UnitedHealth Group stake by 40.8% in Q2, reducing holdings to 8,979 shares valued at approximately $2.8 million.
Institutional and hedge fund ownership of UnitedHealth Group is now 87.86%, reflecting ongoing portfolio adjustments by major investors.
Options activity on UnitedHealth Group has risen, with large investors showing a more bearish stance amid recent market developments.

Bearish institutional shifts as major investors reduce UNH exposure

Frank Rimerman Advisors LLC significantly reduced its holdings in UnitedHealth Group by 40.8% during the second quarter, lowering its position to 8,979 shares valued at about $2.8 million. Other institutional investors also adjusted their UNH stakes, with overall institutional and hedge fund ownership now at 87.86%. Options activity has increased recently, showing heightened interest from large investors who have adopted a more bearish stance.

Oversold signals emerge amid intraday volatility and bearish momentum

Momentum signals are firmly bearish, with both daily and weekly MACD indicating a sell bias and ADX values remaining neutral but low, implying a weak trend. Oscillators highlight oversold conditions: the RSI (36.68), CCI (-81.27), and multiple timeframes of the Stoch RSI point to potential exhaustion in the recent sell-off, though BBP signals decisive intraday seller control. The Awesome Oscillator direction aligns with the bearish view. After a small opening gap lower (from $320.39 to $316.78), the price has drifted down nearly 3%, trading toward the low end of today's $308.86 – $317.09 range amidst high intraday volatility and continued pressure following the open. Some divergence is evident as oversold signals develop alongside bearish momentum, but sellers remain dominant intraday.

Sideways trade expected as downside risk outweighs bullish scenario

For the short term, the expected trading range for the next five days is $308 to $320, maintaining a realistic corridor around the current price. There is a very low probability (less than 20%) of a significant upside move, while the likelihood of continued pressure or further declines remains much higher. The baseline scenario is sideways movement between $308 and $320 as bearish momentum slows. A bullish scenario would require a firm break above $320 with follow-through strength, targeting resistance levels near $347. In a bearish move, sustained closes below $308 could open the way for deeper declines, but oversold readings may begin to counteract further downside.

Viktoras Karapetjanc, expert at Traders Union, sees recent selling in UnitedHealth Group as persistent but believes the oversold technical signals may soon limit further downside. He notes rising bearish sentiment among institutional investors and increased options activity, even as the price tests lower ranges. Karapetjanc expects sideways movement between $308 and $320 in the near term, with a constructive outlook if the stock decisively reclaims $320. "I remain optimistic that once this short-term pressure eases, stronger demand from major investors and stabilization in oversold technicals could fuel a meaningful recovery toward key resistance," he says.

Previously it was noted that UnitedHealth Group experienced ongoing selling pressure and technical weakness, with momentum indicators showing strong bearishness. Regulatory investigation risks remained prominent, as the company was responding to issues related to Medicare billing and institutional investor activity, with further coverage available in the article regulatory investigation risks remained prominent.

Source of Data: UNH Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.